Form 4: Quest Diagnostics SVP Acquires Shares via DRIP

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, acquired 46 shares of common stock through a dividend reinvestment plan.

Summary

• Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics Inc. (DGX), acquired 46 shares of common stock.
• The acquisition occurred on October 21, 2025, at a price of $189.079 per share.
• These shares were acquired through a dividend reinvestment plan (DRIP) and were reported early on this Form 4, though eligible for deferred reporting on Form 5.
• Following this transaction, Plewman beneficially owns 15,333 shares of Quest Diagnostics common stock.
• The total beneficial ownership includes exempt purchases made under the company's stock purchase plan since the last Form 4 filing.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The acquisition of shares by a senior officer, even a small amount through a dividend reinvestment plan, generally indicates management confidence in the company's future prospects. The use of a 10b5-1 plan suggests a systematic, pre-planned approach to increasing ownership, which is a mild positive.

Positives

• An executive, Patrick Plewman, is increasing his direct ownership in the company, which can signal confidence in future performance.
• The acquisition was made through a dividend reinvestment plan, indicating a long-term investment strategy.
• The transaction was executed under a Rule 10b5-1(c) plan, suggesting a pre-planned, systematic approach to share acquisition.

Future Outlook

The filing does not provide any explicit forward-looking statements or guidance.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• The acquisition of common stock by Patrick Plewman, an SVP of Quest Diagnostics, is a related party transaction.

Stakeholder Impact

• Shareholders may view the insider purchase as a positive signal of management confidence in the company's future.

Key Dates

Recommendation

While an insider acquisition, even a small one through a dividend reinvestment plan, can be seen as a positive signal of management confidence, this specific transaction is not substantial enough to warrant a 'buy' recommendation. It reinforces a 'hold' position for existing investors, as it doesn't present new significant catalysts or concerns.

Keywords

Quest Diagnostics, DGX, Insider Trading, Form 4, Stock Acquisition, Plewman Patrick, Dividend Reinvestment Plan, SVP, Officer Transaction, 10b5-1 Plan